BioNTech Shares Plunge as Pfizer Exits Stake

A seismic development has rocked BioNTech’s stock valuation following the complete divestment of Pfizer’s substantial shareholding. The long-standing pandemic partner executed an accelerated block trade, offloading its entire remaining position of 4.55 million shares overnight, sending the biotechnology firm’s equity into a tailspin. This dramatic separation raises critical questions about the strategic implications for the Mainz-based company’s future trajectory.

Quarterly Results Overshadowed by Strategic Shift

Amid the market turmoil triggered by Pfizer’s exit, BioNTech had previously released third-quarter 2025 financial results that presented a mixed performance picture. Revenue figures provided a positive surprise, with the company generating €1.52 billion, substantially exceeding market expectations. This outperformance was primarily driven by a significant payment received through the collaboration with Bristol Myers Squibb.

However, the bottom line told a different story, revealing a net loss of €28.7 million. This translates to a negative net margin of 1.9 percent and a per-share loss of approximately €0.12, contrasting with analyst projections that had anticipated a modest profit. On a more optimistic note, BioNTech raised its full-year revenue guidance to a range between €2.6 billion and €2.8 billion.

Complete Liquidation of Partnership Stake

Pfizer’s decisive move involved the overnight sale of its remaining BioNTech holdings, valued at up to $508 million. According to an official stock market filing, the pharmaceutical giant reduced its stake by a substantial 54.7 percent, effectively eliminating its entire position in the German biotech firm.

Should investors sell immediately? Or is it worth buying BioNTech?

The market response proved severe. BioNTech shares opened with a significant price gap at $105.50, a notable decline from the previous day’s closing price of $111.70. Company management attempted to reassure investors, with a spokesperson emphasizing that the collaborative relationship remains “close and strong.” Despite these assurances, investor confidence has been visibly shaken.

Divergent Analyst Perspectives Emerge

As BioNTech’s stock faces sustained pressure, market experts remain divided in their assessments. Analysts at H.C. Wainwright demonstrated continued optimism, elevating their price target from $136 to $140 while reaffirming their buy recommendation. This positive outlook was attributed to the company’s declining operational expenses.

The broader market consensus, however, has shifted to a more cautious “moderate buy” stance, with price targets from various financial institutions showing significant dispersion. The stock continues to contend with a well-established downward trend, and Pfizer’s complete withdrawal has undoubtedly left its mark. Market participants are now critically reevaluating their confidence in the BioNTech growth narrative.